Corneal Thinning During Topical Bevacizumab Therapy

This study has been withdrawn prior to enrollment.
(Side effect can increase the risk of the research)
Information provided by:
Yonsei University Identifier:
First received: August 13, 2007
Last updated: April 29, 2015
Last verified: April 2015
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Condition Intervention
Corneal Neovascularization
Drug: bevacizumab (Avastin)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Enrollment: 0
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Both

Inclusion Criteria:

  • clinical diagnosis of corneal neovascularization
  • must be able to apply eyedrop

Exclusion Criteria:

  • have active keratitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00515684

Korea, Republic of
Severance hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
Principal Investigator: Sang Woo Kim, M.D. Severance hospital, Seoul , Korea
  More Information Identifier: NCT00515684     History of Changes
Other Study ID Numbers: 4-2006-0234 
Study First Received: August 13, 2007
Last Updated: April 29, 2015
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Corneal Neovascularization
Neovascularization, Pathologic
Corneal Diseases
Eye Diseases
Pathologic Processes
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs processed this record on May 24, 2016